Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
E.F. Neufeld, J. Muenzer.
The mucopolysaccharidosis.
The metabolic and molecular bases of inherited disease, 7th, pp. 2465-2494
[2.]
Garcia Ruiz PJ, Perez Higueras A, Quiñones D, Escorihuela R, Castillo F. Posterior CT guided approach for botulinum toxin injection into spinal psoas. J Neurol 2002 (en prensa).
[3.]
Maryland, (1900),
[4.]
R. Pellizzari, O. Rosetto, G. Schiavo, C. Montecucco.
Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses.
Philos Trans R Soc Lond B Biol Sci, 354 (1999), pp. 259-268
[5.]
C. Singer.
Indicaciones y manejo de la toxina botulínica.
Rev Neurol, 29 (1999), pp. 157-162
[6.]
J.M. Freeman, K.B. Nelson.
Intrapartum asphysia and cerebral palsy.
Pediatrics, 82 (1988), pp. 240-249
[7.]
A.P. Cosgrove, I.S. Corry, H.K. Graham.
Botulin toxin in the management of the lower limb in cerebral palsy.
Dev Med Child Neurol, 36 (1994), pp. 386-396
[8.]
R. Boyd, H.K. Graham.
Botulinum toxin A in the management of children with cerebral palsy. Indications outcome.
Eur J Neurol, 4 (1997), pp. 15-22
[9.]
L.A. Koman, J.F. Mooney 3rd, B. Smith, A. Goodman, T. Mulvaney.
Management of cerebral palsy with botulinum-A toxin: Preliminary investigation.
J Pediatr Orthop, 13 (1993), pp. 489-495
[10.]
A. Tylki-Szywanska, B. Czartoryska, D. Gorska.
Piesiewicz-Grzonkowska E. Type III D mucopolysaccharidosis (Sanfilippo D): Clinical course and symptoms.
Acta Paediatr Jpn, 4 (1998), pp. 492-494
Copyright © 2003. Asociación Española de Pediatría
